These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35443747)

  • 61. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries.
    Pan Y; Du J; Liu J; Wu H; Gui F; Zhang N; Deng X; Song G; Li Y; Lu J; Wu X; Zhan S; Jing Z; Wang J; Yang Y; Liu J; Chen Y; Chen Q; Zhang H; Hu H; Duan K; Wang M; Wang Q; Yang X
    Cell Discov; 2021 Jul; 7(1):57. PubMed ID: 34315862
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
    Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH
    J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Structural and functional analysis of a potent sarbecovirus neutralizing antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    bioRxiv; 2020 Apr; ():. PubMed ID: 32511354
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.
    Yang Z; Wang Y; Jin Y; Zhu Y; Wu Y; Li C; Kong Y; Song W; Tian X; Zhan W; Huang A; Zhou S; Xia S; Tian X; Peng C; Chen C; Shi Y; Hu G; Du S; Wang Y; Xie Y; Jiang S; Lu L; Sun L; Song Y; Ying T
    Signal Transduct Target Ther; 2021 Nov; 6(1):378. PubMed ID: 34732694
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape.
    Starr TN; Czudnochowski N; Zatta F; Park YJ; Liu Z; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Tucker H; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Cameroni E; Croll TI; Nix JC; Havenar-Daughton C; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Whelan SPJ; Virgin HW; Veesler D; Corti D; Bloom JD; Snell G
    bioRxiv; 2021 Apr; ():. PubMed ID: 33851154
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery.
    Milazzo FM; Chaves-Sanjuan A; Minenkova O; Santapaola D; Anastasi AM; Battistuzzi G; Chiapparino C; Rosi A; Merlo Pich E; Albertoni C; Marra E; Luberto L; Viollet C; Spagnoli LG; Riccio A; Rossi A; Santoro MG; Ballabio F; Paissoni C; Camilloni C; Bolognesi M; De Santis R
    Mol Ther; 2023 Feb; 31(2):362-373. PubMed ID: 36114671
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models.
    Cohen AA; van Doremalen N; Greaney AJ; Andersen H; Sharma A; Starr TN; Keeffe JR; Fan C; Schulz JE; Gnanapragasam PNP; Kakutani LM; West AP; Saturday G; Lee YE; Gao H; Jette CA; Lewis MG; Tan TK; Townsend AR; Bloom JD; Munster VJ; Bjorkman PJ
    bioRxiv; 2022 Mar; ():. PubMed ID: 35378752
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth.
    Ku Z; Xie X; Lin J; Gao P; Wu B; El Sahili A; Su H; Liu Y; Ye X; Tan EY; Li X; Fan X; Goh BC; Xiong W; Boyd H; Muruato AE; Deng H; Xia H; Zou J; Kalveram BK; Menachery VD; Zhang N; Lescar J; Shi PY; An Z
    Nat Commun; 2022 Sep; 13(1):5552. PubMed ID: 36138032
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 73. An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19.
    Rappazzo CG; Tse LV; Kaku CI; Wrapp D; Sakharkar M; Huang D; Deveau LM; Yockachonis TJ; Herbert AS; Battles MB; O'Brien CM; Brown ME; Geoghegan JC; Belk J; Peng L; Yang L; Scobey TD; Burton DR; Nemazee D; Dye JM; Voss JE; Gunn BM; McLellan JS; Baric RS; Gralinski LE; Walker LM
    bioRxiv; 2020 Nov; ():. PubMed ID: 33236009
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Potent universal-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody.
    Piepenbrink MS; Park JG; Desphande A; Loos A; Ye C; Basu M; Sarkar S; Chauvin D; Woo J; Lovalenti P; Erdmann NB; Goepfert PA; Truong VL; Bowen RA; Walter MR; Martinez-Sobrido L; Kobie JJ
    bioRxiv; 2022 Mar; ():. PubMed ID: 35291292
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The diversity of the glycan shield of sarbecoviruses closely related to SARS-CoV-2.
    Allen JD; Ivory D; Ge Song S; He WT; Capozzola T; Yong P; Burton DR; Andrabi R; Crispin M
    bioRxiv; 2022 Aug; ():. PubMed ID: 36052375
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage.
    Jiang W; Zhang Z; Zhu Y; Chen B; Gu C; Liu Z; Zhang X; Xiong H; Zhang Y; Zheng B; Wang R; Jiao S; Wang A; Zhang T; Zhang J; Wang S; Zhang B; Li G; Gui X
    Front Pharmacol; 2022; 13():926750. PubMed ID: 35873586
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth.
    Ku Z; Xie X; Lin J; Gao P; El Sahili A; Su H; Liu Y; Ye X; Li X; Fan X; Goh BC; Xiong W; Boyd H; Muruato AE; Deng H; Xia H; Jing Z; Kalveram BK; Menachery VD; Zhang N; Lescar J; Shi PY; An Z
    bioRxiv; 2022 Feb; ():. PubMed ID: 35132410
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants.
    Cho H; Gonzales-Wartz KK; Huang D; Yuan M; Peterson M; Liang J; Beutler N; Torres JL; Cong Y; Postnikova E; Bangaru S; Talana CA; Shi W; Yang ES; Zhang Y; Leung K; Wang L; Peng L; Skinner J; Li S; Wu NC; Liu H; Dacon C; Moyer T; Cohen M; Zhao M; Lee FE; Weinberg RS; Douagi I; Gross R; Schmaljohn C; Pegu A; Mascola JR; Holbrook M; Nemazee D; Rogers TF; Ward AB; Wilson IA; Crompton PD; Tan J
    bioRxiv; 2021 Apr; ():. PubMed ID: 33821267
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Development of T cell antigen-based human coronavirus vaccines against nAb-escaping SARS-CoV-2 variants.
    Zhou H; Leng P; Wang Y; Yang K; Li C; Ojcius DM; Wang P; Jiang S
    Sci Bull (Beijing); 2024 Jun; ():. PubMed ID: 38942698
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chimeric spike mRNA vaccines protect against Sarbecoviru
    Martinez DR; Schäfer A; Leist SR; De la Cruz G; West A; Atochina-Vasserman EN; Lindesmith LC; Pardi N; Parks R; Barr M; Li D; Yount B; Saunders KO; Weissman D; Haynes BF; Montgomery SA; Baric RS
    bioRxiv; 2021 May; ():. PubMed ID: 33758837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.